Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.
Authors
Zhenggang Ren
Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China;
Zhenggang Ren , Yabing Guo , Yuxian Bai , Jieer Ying , Zhiqiang Meng , Zhendong Chen , Shanzhi Gu , Jingdong Zhang , Jun Liang , Xinfang Hou , Wei Li , Aibing Xu , Chunyi Hao , Jian Zhang , Ruijun Xing , Xinyu Zhang , Dan Zhang , Stephen Lam Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04212221
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 578)
DOI
10.1200/JCO.2023.41.4_suppl.578
Abstract #
578
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2019 ASCO Annual Meeting
First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
First Author: Masatoshi Kudo
Poster
2019 Gastrointestinal Cancers Symposium
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo
Poster
2017 Gastrointestinal Cancers Symposium
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
First Author: Ignacio Melero